Our xTAG® and MultiCode™-RTx Technologies serve a wide range of clinical applications, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.
Read More
Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.
Read More
Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® technology. Click here to start the conversation now.
Learn More
The Faces of Luminex: Carrie Prehoda, Accounting
Keeping the financial statements for any company is a critical job, but especially so for a publicly traded firm like Luminex that has to report its finances to the U.S. Securities and Exchange Commission. We trust our data to Carrie Prehoda, Manager of Accounting and Stock Plan Administration, who joined the company in 2016.
Continue Reading >
xMAP Technology makes up the basis of Luminex’s core business. This flexible technology is centered on the use of Luminex xMAP Microspheres.
Watch more videos >
February 4
Luminex Corporation Reports Fourth Quarter and Full-Year 2018 Financial Results
January 2
Luminex Corporation Completes Acquisition of MilliporeSigma’s Flow Cytometry Portfolio
November 5
Luminex Corporation Reports Third Quarter 2018 Financial Results
October 18
Luminex Corporation to Acquire MilliporeSigma’s Flow Cytometry Portfolio
October 15
Luminex Corporation Third Quarter Earnings Release Scheduled for November 5, 2018
xMAP® Connect Amsterdam
6-7 November
Amsterdam, Netherlands
